01 Industry overview
The microfluidics industry at a glance
The global microfluidics market is estimated at $46.9 billion in 2026 and is expanding as lab-on-a-chip, diagnostics, genomics and organ-on-chip applications gain adoption.
- $46.9B[3]
- Market size, 2026
- 12.2%[3]
- Forecast CAGR, 2026–2033
- 42.8%[3]
- North America share, 2025
- 35%[4]
- Top-five company share, 2025
- Market size
- The global microfluidics market was valued at $41.9 billion in 2025 and is estimated at $46.9 billion in 2026. Grand View Research projects the market to reach $105.1 billion by 2033.[3]
- Forecast & CAGR
- The market is forecast to grow at a 12.2% compound annual growth rate from 2026 to 2033. A separate 2025 estimate from Global Market Insights places the 2026–2034 CAGR at 14.9%, illustrating the range of published forecasts.[3][4]
- Market share & regions
- North America held 42.8% of global microfluidics revenue in 2025 and was the largest regional market. Asia Pacific is identified as the fastest-growing region during 2026–2033.[3]
- Segmentation
- Lab-on-a-chip held the largest technology share at 38.71% in 2025, while PDMS accounted for 34.99% of revenue by material. Medical applications generated the largest application contribution in the same year.[3]
- Key players & concentration
- Global Market Insights identifies Danaher as the leading company with more than 11% market share in 2025. The five leading companies—Danaher, Illumina, Thermo Fisher Scientific, PerkinElmer and Agilent Technologies—collectively held 35% of the market.[4]
- Pricing
- Microfluidic chip pricing varies widely by material, fabrication method and production volume: paper chips can cost less than $0.10, while commercial glass chips can cost $50–$500 or more. Prototype PDMS chips are typically quoted at $30–$80 each after labor, cleanroom time and mold costs.[12]
- Trends, drivers & challenges
- Growth is being driven by point-of-care diagnostics, personalized medicine, genomics, drug discovery and organ-on-chip development. Key constraints include high fabrication costs, difficulty scaling prototype processes to volume manufacturing and the need for standardized production and validation.[3][13]
- Consumer behavior & competition
- Demand is shifting toward decentralized and point-of-care testing because microfluidic platforms use small sample and reagent volumes and can shorten turnaround times. Competition combines large life-science suppliers—including Danaher, Illumina, Thermo Fisher Scientific and Agilent—with specialized diagnostic, genomic and chip-manufacturing companies.[4][3]
- M&A
- In November 2026, ARCHIMED completed its acquisition of Standard BioTools’ microfluidics business for $5.0 million, with the business renamed Biomark Scientific. The transaction creates a standalone provider focused on genomic workflows using integrated fluidic circuits.[14]
- Latest news
- The most recent major corporate development identified was the November 3, 2026 completion of ARCHIMED’s acquisition of Standard BioTools’ microfluidics business. The acquired business operates as Biomark Scientific and continues to develop automated PCR, qPCR and NGS library-preparation systems based on proprietary microfluidics.[14]
02 Ranking
Top 10 Companies in the Microfluidics Industry
The leading companies in the microfluidics industry, ranked on market impact, performance, momentum, innovation and brand popularity.
Updated November 21, 2026 · Next review December 21, 2026
Thermo Fisher Scientific stands out for commercializing microfluidic consumables because it is commercializing next-generation consumables for molecular biology and diagnostic microfluidics, while Agilent Technologies focuses on automated electrophoresis and microfluidics since it reports automated electrophoresis and microfluidics among its life-science technologies.
Ranked by Overall score · How we score ↓
Editor's top 3 picks
Where to start, by need.
#1 Overall · Leader in microfluidic consumables
Thermo Fisher Scientific
US
Ranked #1 · 9.2 · Microfluidic consumables
Why we picked it: It commercializes next-generation consumables for molecular biology and diagnostic microfluidics, with an operating margin of 17.4%.
Leader in microfluidic instruments and reagents
Agilent Technologies
US
Ranked #2 · 9.1 · Microfluidic instruments and reagents
Why we picked it: Automated electrophoresis and microfluidics sit inside its life-science technology set, supported by a 21.3% operating margin in 2025.
Leader in automated microfluidic platforms
Roche
CH
Ranked #3 · 9.1 · Automated microfluidic platforms
Why we picked it: It operates in microfluidic point-of-care testing, backed by a 19.8% R&D share of revenue in 2025.
Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.
Full ranking
| # | Company | Overall ↓ | Impact | Performance | Momentum | Innovation | Company snapshot |
|---|---|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific Microfluidic consumables · US | 9.2 | 9.9 | 9.2 | 9.3 | 7.0 | |
Company snapshot · Thermo Fisher Scientific · Data as of November 21, 2026 Thermo Fisher is commercializing next-generation consumables for molecular biology and diagnostic microfluidics.[15]
| |||||||
| 2 | Agilent Technologies Microfluidic instruments and reagents · US | 9.1 | 9.1 | 9.7 | 9.4 | 7.6 | |
Company snapshot · Agilent Technologies · Data as of November 21, 2026 Agilent reports automated electrophoresis and microfluidics among its life-science technologies.[16]
| |||||||
| 3 | Roche Automated microfluidic platforms · CH | 9.1 | 8.4 | 9.3 | 9.8 | 9.9 | |
Company snapshot · Roche · Data as of November 21, 2026 Roche is listed among the major companies in microfluidic point-of-care testing.[17]
| |||||||
| 4 | Illumina Microfluidic consumables · US | 9.0 | 9.1 | 8.9 | 8.4 | 9.9 | |
Company snapshot · Illumina · Data as of November 21, 2026 Illumina is identified among the leading companies in the global microfluidics market.[7]
| |||||||
| 5 | QIAGEN Automated microfluidic platforms · NL | 9.0 | 8.4 | 9.7 | 9.0 | 8.6 | |
Company snapshot · QIAGEN · Data as of November 21, 2026 QIAGEN's QIAstat-Dx cartridges use pneumatically operated microfluidics for automated molecular testing.[18]
| |||||||
| 6 | Hesperos Multi-organ microfluidic systems · US | 8.7 | 7.0 | 9.9 | 9.9 | 9.2 | |
Company snapshot · Hesperos · Data as of November 21, 2026 Hesperos offers multi-organ human-on-chip systems using microfluidic tissue models.[19]
| |||||||
| 7 | Elveflow Microfluidic flow control instruments · FR | 8.6 | 7.6 | 9.3 | 9.4 | 8.6 | |
Company snapshot · Elveflow · Data as of November 21, 2026 Elveflow sells microfluidic flow controllers, valves, sensors and pressure-control systems.[20]
| |||||||
| 8 | 10x Genomics Single-cell droplet microfluidics · US | 8.4 | 8.4 | 8.0 | 8.2 | 9.2 | |
Company snapshot · 10x Genomics · Data as of November 21, 2026 Chromium instruments use microfluidic chips to generate gel-bead emulsions for single-cell analysis.[21]
| |||||||
| 9 | Danaher Diagnostics and life-science microfluidics · US | 8.4 | 8.7 | 9.2 | 8.5 | 8.0 | |
Company snapshot · Danaher · Data as of November 21, 2026 SCIEX, part of Danaher, sells the Intabio ZT microfluidic chip-based platform.[22]
| |||||||
| 10 | Bio-Rad Laboratories Droplet microfluidics and digital PCR · US | 8.3 | 9.0 | 7.8 | 7.7 | 8.4 | |
Company snapshot · Bio-Rad Laboratories · Data as of November 21, 2026 Bio-Rad's ddPCR systems use microfluidics to partition samples into water-in-oil droplets.[23]
| |||||||
How we score
- Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
- Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
- Momentum (20%): growth trajectory and future potential.
- Innovation (15%): R&D intensity and how technologically advanced the company is.
Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.
Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.
Cadence Recalculated when new figures are published; next review December 21, 2026.
Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.
Cite this ranking
APA
Samuel Norberg. (2026, November 21). Top 10 companies in the microfluidics industry. In Microfluidics Industry Statistics. Gitnux. https://gitnux.org/microfluidics-industry-statistics/#top-companies
Bio-MEMS and microfluidics market share by region
North America holds the largest share at 40.2%.
03 Trends & forecasts
Top 10 Microfluidics Industry Trends & Forecasts 2027
What is changing in the microfluidics industry, with the evidence behind each trend and a forecast for 2027.
Forecasts were generated by an AI model from the cited evidence. They are estimates, not guarantees.
01Market growth remains double-digit
High confidenceGrand View Research estimates the global microfluidics market at $41.9 billion in 2025 and $46.9 billion in 2026, with a projected 12.2% CAGR from 2026 to 2033. The forecast implies a market of roughly $52.6 billion in 2027 if growth is sustained.[3]
Forecast 2027: The market should approach $52–53 billion in 2027, supported by diagnostics, genomics and pharmaceutical research. Growth will remain uneven because commercial adoption is faster in established laboratory workflows than in regulated clinical testing.
02Point-of-care adoption broadens
High confidenceMicrofluidics-based in-vitro diagnostics are forecast by Grand View Research to grow from $8.2 billion in 2026 to $13.8 billion in 2033, while point-of-care diagnostics accounted for 38.53% of microfluidics revenue in 2025 in a separate market estimate. Recent reviews identify rapid, decentralized testing as the main translation target for microfluidic platforms.[3][7][24]
Forecast 2027: In 2027, more platforms will combine sample preparation, amplification, detection and digital reporting in one cartridge. Adoption will be strongest where rapid results change treatment decisions, including infectious disease, coagulation and reproductive testing.
03Genomics drives integrated workflows
High confidenceIllumina reported that its revenue increased 6% year over year to $3.38 billion in year-to-date 2026, primarily because of demand for NovaSeq X instruments and related consumables. Standard BioTools’ former microfluidics business also operates a platform for automated PCR, qPCR and NGS library preparation using integrated fluidic circuits.[25][26]
Forecast 2027: In 2027, microfluidics suppliers will increasingly sell complete genomic workflows rather than standalone chips. The strongest opportunities will be multiplex PCR, targeted sequencing, single-cell analysis and sample-to-answer library preparation.
04Organ-on-chip moves toward validation
High confidenceThe U.S. Government Accountability Office describes organ-on-chip technology as promising for human-relevant drug research but identifies limited benchmarks, insufficient validation studies, difficulty obtaining high-quality human cells and unclear regulatory guidance. The FDA has already used organ-on-chip systems in research and development agreements.[27][28]
Forecast 2027: In 2027, organ-on-chip growth will be concentrated in pharmaceutical screening, toxicity testing and method-development partnerships rather than routine regulatory replacement of animal studies. Demand for standardized cell sources, reference methods and interlaboratory validation will rise.
05Digital microfluidics gains practical traction
Medium confidenceA 2026 review describes digital microfluidics as a scalable platform for biomedical applications, with portable architectures using components such as Raspberry Pi boards and integrated optical or electrochemical sensors. The same review notes that clinical adoption remains limited compared with established technologies.[29][30]
Forecast 2027: In 2027, digital microfluidics will expand mainly in research automation, decentralized assays and modular diagnostic instruments. Commercial progress will depend on improving reproducibility, reagent handling and regulatory evidence rather than on miniaturization alone.
06Paper microfluidics targets low-cost testing
Medium confidenceA 2026 Royal Society of Chemistry review identifies low cost, portability, ease of operation and design flexibility as continuing advantages of microfluidic paper-based analytical devices. It also reviewed nearly 100 recent examples and found that real-world translation still depends on clinical-sample validation, storage stability and simpler operation.[31]
Forecast 2027: In 2027, paper-based formats will gain incremental use in infectious-disease screening, environmental monitoring and resource-limited settings. Products that include stable reagents and minimal sample preparation will outperform laboratory demonstrations.
07Manufacturing shifts toward scalable plastics
High confidenceA 2026–2027 European research work programme specifically calls for design-for-manufacture of microfluidic cartridges and scalability to injection-moulded and roll-to-roll parts. This reflects the industry’s continuing need to move beyond small-batch academic fabrication.[32]
Forecast 2027: In 2027, higher-volume products will increasingly use injection-moulded polymers, laminated films and automated assembly. PDMS will remain important for prototyping and research, but its relative position will weaken in disposable products requiring low unit cost and long shelf life.
08Integrated sensing reduces instrument burden
Medium confidenceA 2026 review reports that integrated microfluidic biosensors combine sample handling with real-time detection and can improve sensitivity, speed, portability and immediate monitoring. It highlights dielectrophoresis, acoustofluidics, inertial microfluidics and optofluidics as enabling approaches for selective enrichment and detection.[31]
Forecast 2027: In 2027, more systems will integrate enrichment, reaction control and optical or electrochemical readout on the same disposable or cartridge. This will support smaller readers and reduce dependence on centralized laboratory equipment, although assay validation will remain a bottleneck.
09Regulatory requirements become more demanding
High confidenceThe FDA’s Quality Management System Regulation became effective on February 2, 2026, incorporating ISO 13485:2016 requirements into U.S. medical-device quality controls. In Europe, IVDR requires applicable in-vitro diagnostic products to meet general safety and performance requirements, with notified-body assessment for many products that previously avoided it.[28][33]
Forecast 2027: In 2027, documentation, design controls, clinical evidence and post-market surveillance will become more important sources of competitive differentiation. Smaller developers will increasingly partner with established manufacturers or specialist regulatory organizations to reach market.
10Asia-Pacific expands faster
High confidencePublished market estimates identify Asia-Pacific as the fastest-growing regional market through 2033, while North America held 42.8% of global microfluidics revenue in 2025. The cited market analysis links Asia-Pacific growth to increasing investment in diagnostic infrastructure in China, India and Japan.[3][7]
Forecast 2027: In 2027, Asia-Pacific should gain share through public-health testing, biopharmaceutical manufacturing and research infrastructure. North America will remain the largest regional market, but local partnerships and manufacturing access will become more important for suppliers entering Asian markets.
04 Statistics
Technology
Patent activity stays measurable but uneven: 28,212 micro- and mesofluidics patents were identified across approximately 2015–2024, with the 2024 complete-year record count down to 60.
R&D, patents and design rights in the microfluidics industry
- 28,212 patents were identified in a micro- and mesofluidics patent search covering approximately 2015–2024; the source uses patent records rather than a formal industry classification.[1]
- 60 complete-year published patent records were identified for lab-on-a-chip and microfluidics in 2024, down 18% from 73 records in 2021.[2]
- 49.3% of 28,212 micro- and mesofluidics patents in the study were filed in the United States, equal to 12,995 records.[1]
05 Statistics
Market Intelligence
Revenue baselines are split across different market definitions in 2025, while 2026–2033 growth remains forecast at 12.2% CAGR to reach $105.1 billion by 2033.
Market size, volume and shipments in the microfluidics industry
- US$41.9 billion was the global microfluidics market value in 2025, measured as revenue across product, technology, material, application and regional segments.[3]
- US$35.9 billion was the global microfluidics market value in 2025, covering microfluidics devices and components across medical and non-medical applications.[4]
- US$10.33 billion was the global microfluidics market value in 2025, covering the publisher’s microfluidics industry definition across diagnostic, research and therapeutic applications.[5]
- US$42.71 billion was the global microfluidics market value in 2025, covering microfluidics-based devices and components across medical and non-medical applications.[6]
- US$24.15 billion was the global microfluidics market value in 2025, covering microfluidic components and devices across applications, materials and regions.[7]
- US$24.96 billion was the global microfluidics market value in 2025, covering microfluidics-based devices and components across diagnostics, research and therapeutics; MarketsandMarkets reports revenue, not physical shipments.[8]
Forecast growth and shipments in the microfluidics industry
- The global microfluidics market is projected to reach US$46.13 billion by 2031 from US$26.90 billion in 2026, implying an 11.39% CAGR over 2026–2031.[7]
- The global microfluidics market is projected to reach US$20.73 billion by 2030 from US$11.89 billion in 2026, implying a 14.9% CAGR over 2026–2030.[5]
- The global microfluidics market is projected to reach US$124.2 billion by 2034 from US$40.9 billion in 2026, implying a 14.9% CAGR over 2026–2034.[4]
- The global microfluidics market is projected to reach US$37.19 billion by 2030 from US$24.96 billion in 2025, implying an 8.3% CAGR over 2025–2030.[8]
- The global microfluidics market is projected to reach US$122.35 billion by 2034 from US$48.01 billion in 2026, implying a 12.40% CAGR over 2026–2034.[6]
- The global microfluidics market is projected to reach US$105.1 billion by 2033 from US$46.9 billion in 2026, implying a 12.2% CAGR over 2026–2033.[3]
06 Statistics
Product & Standards
Material mix matters for evaluation: polymers represented 45.7% of global microfluidics market revenue in 2025, while glass and silicon contributed 21.3% and 16.2% to microfluidic-systems revenue.
Materials, inputs and substitution in microfluidics
- Polymers represented 45.7% of global microfluidics market revenue in 2025, covering polymer-based microfluidic devices and systems by material.[9]
- Glass represented 21.3% of global microfluidic-systems market revenue in 2025, measured as the glass material segment.[10]
- Silicon represented 16.2% of global microfluidic-systems market revenue in 2025, measured as the silicon material segment.[10]
07 Statistics
Customers & Channel
Channel spend is consumables-heavy: microfluidic consumables generated 66.7% of global microfluidics market value in 2025, while 36.5% came from chips and cartridges in 2024.
Demand by end use for microfluidics
- 36.5% of global microfluidics market value came from microfluidic chips and cartridges in 2024; the publisher defines the category as chips and cartridges used in lab-on-a-chip, point-of-care diagnostics and screening.[4]
- Clinical diagnostics represented approximately 40% of the global digital microfluidics systems-on-a-chip market by application in 2024; this narrower category covers digital microfluidic systems rather than all microfluidics.[11]
- 66.7% of global microfluidics market value came from microfluidic consumables in 2025, including disposable chips, cartridges, plates, sequencing flow cells, integrated fluidic circuits, diagnostic cards and organ-on-chip plates.[9]
Key questions about the microfluidics industry
What is the size of the microfluidics market in 2026?
How fast is the microfluidics market growing from 2026 to 2033?
Which companies lead the microfluidics industry?
What technology area is taking the largest share of microfluidics revenue?
Which customer spend dominates in microfluidics in 2025?
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
Samuel Norberg. (2026, November 21). Microfluidics Industry Statistics. Gitnux. https://gitnux.org/microfluidics-industry-statistics
Samuel Norberg. "Microfluidics Industry Statistics." Gitnux, 21 Nov 2026, https://gitnux.org/microfluidics-industry-statistics.
Samuel Norberg. 2026. "Microfluidics Industry Statistics." Gitnux. https://gitnux.org/microfluidics-industry-statistics.
Sources & references
33 sources cited across this report
pubs.acs.org
patsnap.com
grandviewresearch.com
gminsights.com
thebusinessresearchcompany.com
fortunebusinessinsights.com
mordorintelligence.com
marketsandmarkets.com
researchandmarkets.com
dataintelo.com
towardshealthcare.com
- flow-matter.com
snsinsider.com
fluidigm.gcs-web.com
jobs.thermofisher.com
annualreports.com
public-pages-files-2025.frontiersin.org
qiagen.com
ntp.niehs.nih.gov
elveflow.com
10xgenomics.com
lifesciences.danaher.com
bio-rad.com
pubmed.ncbi.nlm.nih.gov
investor.illumina.com
- investors.standardbio.com
gao.gov
fda.gov
doi.org
sciencedirect.com
pubs.rsc.org
- microfluidics-innovation-center.com
webgate.acceptance.ec.europa.eu
